• Q3 cash receipts of $13.1M with positive operating cashflow of $2.5M
• Q3 new TCV sales of $48.8M with $11.5M expected to be recognised in FY25
• FY25 contracted (sold and renewal) revenue stands at $40.2M at end of Q3

Alcidion Group Limited (ASX:ALC) has released its Appendix 4C and Quarterly Activities Report for the quarter ended 31 March 2025 (Q3 FY25). Key highlights include Q3 cash receipts of $13.1M with a positive operating cashflow of $2.5M, a material improvement of $3.9M over Q3 FY24. The company also secured Q3 new TCV sales of $48.8M, with $11.5M expected to be recognised in FY25. This included a new $37.5M, 10-year milestone contract with NCIC NHS Trust to deliver a new Electronic Patient Record (EPR) platform, as well as a new 5-year, $5.5M contract with Hywel Dda University Health Board in Wales. Alcidion also renewed several of its existing PCS (PAS) customers, underpinning its recurring revenue and cashflows. At the end of Q3, Alcidion had $40.2M of contracted and scheduled renewal revenue able to be recognised in FY25. The company expects FY25 EBITDA to exceed $3.0M and to deliver a positive full year cashflow result. Alcidion ended the quarter with a cash balance of $10.2M and no debt.

Alcidion expects FY25 EBITDA to exceed $3.0M and to deliver a positive full year cashflow result.

Heading into Q4, historically the strongest quarter for cash receipts, Alcidion is confident of delivering a strong result that will see it cashflow positive for the full year FY25. The company's annually recurring revenue base continues to build, materially boosted by the recent EPR contract in the UK, which contributes further to the long-term value of the business.